ABCL
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- AbCellera announced a presentation of Phase 2 data for ABCL635 at the 2026 IMS World Congress on MenopauseSep 17, 2026
- AbCellera reported positive topline Phase 2 results for ABCL635, showing significant reductions in the frequency and severity of vasomotor symptoms with favorable tolerabilityAug 10, 2026
- AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseasesJul 29, 2026
- AbCellera and Jazz Pharmaceuticals entered a collaboration to develop next-generation T-cell engaging multispecific antibodiesJun 17, 2026
- AbCellera doses first participants in Phase 1 clinical trial of ABCL575Aug 29, 2025